COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine Among Health Professionals in Low-Income Country: Ethiopia
Yoseph Solomon,Tewodros Eshete,Bersabeh Mekasha,Wubshet Assefa
DOI: https://doi.org/10.2147/JMDH.S331140
2021-09-16
Journal of Multidisciplinary Healthcare
Abstract:Yoseph Solomon, 1, &ast Tewodros Eshete, 2, &ast Bersabeh Mekasha, 1, &ast Wubshet Assefa 3, &ast 1 Department of Surgery, School of Medicine, Debre Markos University, Debre Markos, Ethiopia; 2 Department of Health Informatics, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 3 Department of Pathology, School of Medicine, Debre Markos University, Debre Markos, Ethiopia &astThese authors contributed equally to this work Correspondence: Tewodros Eshete Department of Health Informatics, College of Health Sciences, Debre Markos University, P.O. Box: 269, Debre Markos, Ethiopia Tel +251 933086482 Email Purpose: The Oxford–AstraZeneca is one of COVID-19 vaccine which is expected to be mass-produced and plays a critical role in controlling the pandemic that the globe faced. Ethiopia launched the AstraZeneca vaccination and planned to vaccinate 20% of the population by the end of 2021. Health care professionals are one of the eligible groups of the community to receive the vaccine with priority. Although individuals are advised to take the vaccine to protect themselves and the people around them from COVID-19 infection, many are doubtful about the consequences of the vaccine. So, this study assessed the immediate symptoms associated with taking the Oxford–AstraZeneca COVID-19 vaccine. Methods: This online study was conducted from April 15 to 30, 2021 at a national level across health care providers who took their first dose of Oxford–AstraZeneca vaccine in Ethiopia. Results: There were 672 study participants engaged in this study and around 75.8% of health care providers who took the vaccine had injection site symptoms like pain (65.48%) and tenderness (57.89%). Most of them (60%) developed their injection site symptom within 12 hours after vaccination and the symptoms lasted for about 24– 72 hours on most (63.53%) of the participants. Mild symptoms were identified among 70.98% of the study participants; tiredness and headache were the most reported symptoms with 52.08% and 50.15%, respectively. Only 6.1% of participants reported severe symptoms. Conclusion: As like that of other vaccines, the Oxford–AstraZeneca COVID-19 vaccine has some adverse effects and most side effects peaked within the first 24 hours following vaccination and usually lasted 1– 3 days. Severe symptoms were uncommon, but they were found to be a major reason why vaccine recipients did not recommend it to others and did not plan to take their second dose. After receiving the COVID-19 vaccination, recipients should be advised about potential vaccine symptoms, how to handle them, and when and where to seek additional guidance if necessary. Keywords: COVID-19, Ethiopia, health care professionals, Oxford–AstraZeneca Globally, as of 28 June 2021, a total of 180,817,269 confirmed cases of COVID-19, including 3,923,238 deaths were reported to World Health Organization (WHO). On a similar date of access, there have been 275,935 confirmed cases of COVID-19 and 4314 deaths reported in Ethiopia. 1 Besides this, the pandemic has brought the worst global economic contraction of the past 80 years through its multi-sectoral impact such as unemployment, poverty, human development, investment, trade, tourism, transport, manufacturing industries, commodity prices, small and medium-sized enterprises. 2 To overcome the ongoing challenges, the WHO has created Strategic Preparedness and Response Plan 2021 (SPRP2021) which translates the previously learned knowledge into coordinated action. The plan also focuses on strengthening researches and innovation for the effective delivery of safe vaccines as part of the overall strategy to successfully confront the COVID-19 pandemic. 3 To date, the scientific community is working collaboratively and aggressively to develop an efficient and effective vaccine against the SARS-CoV-2 virus with minimal side effects and complications. 4 Across the globe, there are three major categories of COVID-19 vaccines until the end of June 2021: Unlike many other vaccines, which are costly and must be stored at extremely low temperatures, the Oxford–AstraZeneca vaccine can be stored in a regular refrigerator and costs only a few dollars per dose. Furthermore, it is expected to be mass-produced and may play an important role in curbing the pandemic. 6 It has been few months since Ethiopia launched the Oxford AstraZeneca vaccine for COVID-19 and aimed to vaccinate 20% of the population by the end of 2021. As per the National Deployment and Vaccination Plan (NDVP) of Ethiopia, developed following the WHO Prioritizing Roadmap, the fi -Abstract Truncated-
health care sciences & services